Brandon L Ellsworth1, Allan K Metz1, Nicole M Mott1, Ruby Kazemi1, Michael Stover1, Tasha Hughes2,3, Lesly A Dossett4,5. 1. University of Michigan School of Medicine, Ann Arbor, MI, USA. 2. Department of Surgery, Michigan Medicine, Ann Arbor, MI, USA. 3. Center for Healthcare Outcomes and Policy, Michigan Medicine, Ann Arbor, MI, USA. 4. Department of Surgery, Michigan Medicine, Ann Arbor, MI, USA. ldossett@umich.edu. 5. Center for Healthcare Outcomes and Policy, Michigan Medicine, Ann Arbor, MI, USA. ldossett@umich.edu.
Abstract
BACKGROUND: With rising healthcare costs and campaigns aimed at avoiding low-value care, reducing cancer overtreatment has emerged as an important measure of cancer care quality. The extent to which avoidance of low-value care has been incorporated in cancer-specific quality measures is unknown. We aimed to identify and characterize cancer quality measures that promote the avoidance of low-value care, and identify gaps that may guide future measure development. METHODS: We systematically identified cancer-specific quality measures from leading quality measure organizations [e.g., National Quality Forum (NQF), National Quality Measures Clearinghouse (NQMC)]. We reviewed measures promoting the avoidance of low-value cancer care and subclassified them into disease site- or non-disease site-specific categories and the phase of care they targeted. RESULTS: We reviewed 313 quality measures from six organizations. Of these, 18% (n = 55) focused on avoidance of low-value care. Quality measures focused on end-of-life care were most likely to focus on low-value care [n = 13 (50%)], followed by breast [n = 12 (18%)], lung [n = 9 (31%)], colon [n = 8 (20%)], prostate [n = 5 (38%)], general cancer care [n = 4 (3%)], symptoms and toxicities [n = 2 (40%)], and palliative cancer care [n = 2 (11%)] measures. The phases of care quality measures targeted included low-value screening [n = 5 (9%)], diagnostic testing and staging [n = 7 (13%)], treatment [n = 19 (34%)], surveillance [n = 6 (11%)], and clinical outcomes [n = 18 (33%)]. All categories had a treatment-specific quality measure, but no category had a representative measure for every phase of care. DISCUSSION: A minority of cancer quality measures are aimed at avoiding low-value care, and multiple evidence-based recommendations targeting low-value care have not been incorporated.
BACKGROUND: With rising healthcare costs and campaigns aimed at avoiding low-value care, reducing cancer overtreatment has emerged as an important measure of cancer care quality. The extent to which avoidance of low-value care has been incorporated in cancer-specific quality measures is unknown. We aimed to identify and characterize cancer quality measures that promote the avoidance of low-value care, and identify gaps that may guide future measure development. METHODS: We systematically identified cancer-specific quality measures from leading quality measure organizations [e.g., National Quality Forum (NQF), National Quality Measures Clearinghouse (NQMC)]. We reviewed measures promoting the avoidance of low-value cancer care and subclassified them into disease site- or non-disease site-specific categories and the phase of care they targeted. RESULTS: We reviewed 313 quality measures from six organizations. Of these, 18% (n = 55) focused on avoidance of low-value care. Quality measures focused on end-of-life care were most likely to focus on low-value care [n = 13 (50%)], followed by breast [n = 12 (18%)], lung [n = 9 (31%)], colon [n = 8 (20%)], prostate [n = 5 (38%)], general cancer care [n = 4 (3%)], symptoms and toxicities [n = 2 (40%)], and palliative cancer care [n = 2 (11%)] measures. The phases of care quality measures targeted included low-value screening [n = 5 (9%)], diagnostic testing and staging [n = 7 (13%)], treatment [n = 19 (34%)], surveillance [n = 6 (11%)], and clinical outcomes [n = 18 (33%)]. All categories had a treatment-specific quality measure, but no category had a representative measure for every phase of care. DISCUSSION: A minority of cancer quality measures are aimed at avoiding low-value care, and multiple evidence-based recommendations targeting low-value care have not been incorporated.
Authors: David W Baker; Amir Qaseem; P Preston Reynolds; Lea Anne Gardner; Eric C Schneider Journal: Ann Intern Med Date: 2013-01-01 Impact factor: 25.391
Authors: David D Odell; Joseph Feinglass; Kathryn Engelhardt; Steven Papastefan; Shari L Meyerson; Ankit Bharat; Malcolm M DeCamp; Karl Y Bilimoria Journal: J Thorac Cardiovasc Surg Date: 2018-11-13 Impact factor: 5.209
Authors: Michael J Hassett; Melissa E Hughes; Joyce C Niland; Rebecca Ottesen; Stephen B Edge; Michael A Bookman; Robert W Carlson; Richard L Theriault; Jane C Weeks Journal: Med Care Date: 2008-08 Impact factor: 2.983
Authors: Nancy L Keating; Jessica L F Cleveland; Alexi A Wright; Gabriel A Brooks; Laurie Meneades; Lauren Riedel; Jose R Zubizarreta; Mary Beth Landrum Journal: JAMA Netw Open Date: 2021-03-01